Induced pluripotent stem cells: Challenges and opportunities for cancer immunotherapy

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Sachamitr, Patty ^a   Hackett, Simon ^a   Fairchild, Paul Jonathan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; Cytotoxic T cell; Dendritic cell; Immunotherapy; IPS cell; NK cell; Pluripotency

Indexed keywords

CYTOKINE; TUMOR ANTIGEN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; EMBRYONIC STEM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; NATURAL KILLER CELL; PLURIPOTENT STEM CELL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; VDJ RECOMBINATION;

EID: 84900870089     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00176     Document Type: Review

References (87)

1. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med (1964) 15:167-86. doi: 10.1146/annurev.me.15.020164.001123.
2. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res (1970) 13:1-27.
3. Burnet M. Immunological factors in the process of carcinogenesis. Br Med Bull (1964) 20:154-8.
4. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst (1979) 62:353-8.
5. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol Microbiol Scand B Microbiol Immunol (1974) 82:99-106.
6. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A (1982) 79:4718-22. doi:10.1073/pnas.79.15.4718.
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3:991-8. doi:10.1038/ni1102-991.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
9. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2013) 343:152-7. doi:10.1126/science.1246886.
10. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 211:214-24. doi:10.1111/j.0105-2896.2006.00391.x.
11. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 3:3856-93. doi:10.3390/cancers3043856.
12. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) (2002) 16:4-10.
13. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-7. doi:10.1038/256495a0.
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252-64. doi:10.1038/nrc3239.
15. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 11:805-12. doi:10.1038/nrc3153.
16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690.
17. Rasul KI, Kerr DJ. Targeted therapies: cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol (2009) 6:499-500. doi:10.1038/nrclinonc.2009.108.
18. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol (2005) 23:1147-57. doi:10.1038/nbt1137.
19. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf (2009) 8:223-35. doi:10.1517/14740330902750114.
20. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12:265-77. doi:10.1038/nrc3258.
21. Park MY, Kim CH, Sohn HJ, Oh ST, Kim SG, Kim TG. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine (2007) 25:7322-30. doi:10.1016/j.vaccine.2007.08.037.
22. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol (2010) 10:403-14. doi:10.1038/nri2780.
23. Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol (1976) 117:2233-8.
24. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med (1976) 143:1283-8. doi:10.1084/jem.143.5.1283.
25. Sachamitr P, Fairchild PJ. Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy. Expert Rev Clin Immunol (2012) 8:547-55. doi:10.1586/eci.12.45.
26. Banchereau J, Fay J, Pascual V, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found Symp (2003) 252:226-35. doi:10.1002/0470871628.ch17 discussion 235-228, 257-267,.
27. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 33:464-78. doi:10.1016/j.immuni.2010.10.007.
28. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363:411-22. doi:10.1056/NEJMoa1001294.
29. Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol (2004) 15(Suppl 4):iv145-51. doi:10.1093/annonc/mdh919.
30. Robson NC, Hoves S, Maraskovsky E, Schnurr M. Presentation of tumour antigens by dendritic cells and challenges faced. Curr Opin Immunol (2010) 22:137-44. doi:10.1016/j.coi.2010.01.002.
31. Sorensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, et al. Thor Straten P: CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res (2009) 15:1543-9. doi:10.1158/1078-0432.CCR-08-1412.
32. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2009) 58:1-14. doi:10.1007/s00262-008-0568-4.
33. + dendritic cells. J Exp Med (2010) 207:1273-81. doi:10.1084/jem.20100348.
34. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 207:1247-60. doi:10.1084/jem.20092140.
35. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med (2013) 210:1035-47. doi:10.1084/jem.20121103.
36. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 207:1261-71. doi:10.1084/jem.20092618.
37. Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 42:166-81. doi:10.1007/s12026-008-8057-6.
38. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 86:1159-66. doi:10.1093/jnci/86.15.1159.
39. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med (1955) 102:157-77. doi:10.1084/jem.102.2.157.
40. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225:1487-9. doi:10.1126/science.6332379.
41. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med (1984) 159:495-507. doi:10.1084/jem.159.2.495.
42. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod (1984) 3:501-11.
43. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 319:1676-80. doi:10.1056/NEJM198812223192527.
44. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850-4. doi:10.1126/science.1076514.
45. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 23:2346-57. doi:10.1200/JCO.2005.00.240.
46. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 39:49-60. doi:10.1016/j.immuni.2013.07.002.
47. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314:126-9. doi:10.1126/science.1129003.
48. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell (2013) 13:653-8. doi:10.1016/j.stem.2013.11.002.
49. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 29:731-4. doi:10.1038/nbt.1927.
50. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 122:863-71. doi:10.1182/blood-2013-03-490565.
51. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 209:2351-65. doi:10.1084/jem.20120944.
52. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 69:4010-7. doi:10.1158/0008-5472.CAN-08-3712.
53. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol (2005) 17:211-7. doi:10.1016/j.coi.2005.01.007.
54. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105:3051-7. doi:10.1182/blood-2004-07-2974.
55. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother (2009) 32:914-9. doi:10.1097/CJI.0b013e3181b2910f.
56. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature (1981) 292:154-6. doi:10.1038/292154a0.
57. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science (1998) 282:1145-7. doi:10.1126/science.282.5391.1145.
58. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 126:663-76. doi:10.1016/j.cell.2006.07.024.
59. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131:861-72. doi:10.1016/j.cell.2007.11.019.
60. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2008) 26:101-6. doi:10.1038/nbt1374.
61. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature (2011) 474:212-5. doi:10.1038/nature10135.
62. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell (2009) 4:472-6. doi:10.1016/j.stem.2009.05.005.
63. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 7:618-30. doi:10.1016/j.stem.2010.08.012.
64. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol (2008) 26:795-7. doi:10.1038/nbt1418.
65. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science (2013) 341:651-4. doi:10.1126/science.1239278.
66. Obokata H, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H, et al. Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature (2014) 505:641-7. doi:10.1038/nature12968.
67. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science (2012) 339:823-6. doi:10.1126/science.1232033.
68. Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med (2012) 18:245-7. doi:10.1016/j.molmed.2012.04.001.
69. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A (2009) 107:40-5. doi:10.1073/pnas.0912407107.
70. Zhan X, Dravid G, Ye Z, Hammond H, Shamblott M, Gearhart J, et al. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet (2004) 364:163-71. doi:10.1016/S0140-6736(04)16629-4.
71. Fairchild PJ, Brook FA, Gardner RL, Graca L, Strong V, Tone Y, et al. Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol (2000) 10:1515-8. doi:10.1016/S0960-9822(00)00824-1.
72. Tseng SY, Nishimoto KP, Silk KM, Majumdar AS, Dawes GN, Waldmann H, et al. Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med (2009) 4:513-26. doi:10.2217/rme.09.25.
73. Silk KM, Silk JD, Ichiryu N, Davies TJ, Nolan KF, Leishman AJ, et al. Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1(+) dendritic cells. Gene Ther (2012) 19:1035-40. doi:10.1038/gt.2011.177.
74. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol (2004) 5:410-7. doi:10.1038/ni1055.
75. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity (2002) 17:749-56. doi:10.1016/S1074-7613(02)00474-0.
76. +) T cells. Cell Stem Cell (2013) 12:31-6. doi:10.1016/j.stem.2012.12.006.
77. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 31:928-33. doi:10.1038/nbt.2678.
78. + T cells affect the prognosis of hepatocellular carcinoma patients. Digestion (2012) 86:329-37. doi:10.1159/000342801.
79. +Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol (2012) 30:733-58. doi:10.1146/annurev-immunol-020711-075043.
80. + T reg cells. J Exp Med (2006) 203:1701-11. doi:10.1084/jem.20051745.
81. +CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood (2006) 108:4260-7. doi:10.1182/blood-2006-06-027409.
82. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol (2005) 175:5095-103.
83. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med (2013) 2:274-83. doi:10.5966/sctm.2012-0084.
84. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabyashi Y, et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-d-glucosylceramide synthase deficiency. Proc Natl Acad Sci U S A (2003) 100:1849-54. doi:10.1073/pnas.0430327100.
85. Fujii SI, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol (2013) 4:409. doi:10.3389/fimmu.2013.00409.
86. Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y, et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest (2010) 120:2610-8. doi:10.1172/JCI42027.
87. Schattenberg AV, Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr Opin Oncol (2005) 17:617-21. doi:10.1097/01.cco.0000181405.60213.1c.